Our agonist frontrunner 40 shows high selectivity for LXRα and strong therapeuticefficacy in HCC organoids, therefore illustrating a strong potentialfor advancing this lipotoxic treatment strategy to clinical application. This evidence concerns the gene NR1H3 and hepatocellular carcinoma.